Consumers Union, publisher of Consumer Reports, criticizes the Centers for Medicare & Medicaid Service's system for rating Medicare Part D prescription drug plans as meaningless.
The current system for rating and comparing Medicare Part D prescription drug plans (PDPs) is confusing, meaningless, and should be reformed according to Consumers Union, publisher of Consumer Reports. In a letter sent to Kerry Weems, CMS' acting administrator, the consumer organization faulted the rating system for ignoring information such as how much PDPs increased drug prices during the year, or whether a PDP has more lower-cost generics on its drug list than high-priced brands. Instead, the rating system includes information of little use to consumers, like the ease for pharmacist in filling a prescription. CMS recently released information on the 2008 PDPs in preparation for open enrollment, which begins Nov. 15.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
FDA Expands Tenofovir Alafenamide Indication to Treat HBV in Patients as Young as 6
March 28th 2024Tenofovir alafenamide was originally approved by the FDA in 2016 to treat adults with chronic HBV infection with compensated liver disease and in 2022 to treat pediatric patients aged 12 years and older.